Evaluation of Integrin b1vb26-targeted PET Imaging for Malignant Tumors in a Single-center Clinical Study

What this Trial Is About

Researchers are investigating a new PET imaging method targeting integrin b1vb26, a molecule found almost exclusively in cancerous or reconstructed epithelial cells, to improve diagnosis and staging of malignant tumors. This approach aims to overcome limitations of the widely used 18F-FDG PET, which can produce false positives and negatives. Integrin b1vb26 is considered a promising biomarker due to its high specificity to tumor cells and minimal expression in healthy tissues. Participants diagnosed with malignant tumors or suspected lung cancer will undergo both 18F-FDG and 68Ga-Trivehexin PET/CT scans within one week. The new 68Ga-Trivehexin probe has shown favorable characteristics including high affinity for integrin b1vb26 and low background uptake in normal tissues except the kidneys. Its safety and metabolic stability have been supported by initial clinical data. The study will assess and compare the diagnostic performance of these imaging methods for detecting primary tumors, lymph node involvement, and metastases. During the study, participants will receive PET/CT imaging after injection of the 68Ga-Trivehexin tracer without special preparation. Researchers will evaluate diagnostic sensitivity and specificity over two years, comparing findings with standard 18F-FDG scans and correlating tracer uptake with tumor integrin expression. Participants must consent to the trial and will be monitored for any issues while the study follows their tumor status through imaging results and clinical assessments.

Integrin αvβ6-targeted PET in Malignant Tumors